Metallo

Medivir partner Infex Therapeutics receives FDA QIDP designation

Retrieved on: 
Wednesday, January 11, 2023
Medivir, Food, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, QIDP, Metallo, FDA, Pharmaceutical industry

STOCKHOLM, Jan. 11, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that its partner Infex Therapeutics, a leading anti-infectives specialist, has been granted Qualified Infectious Disease Product (QIDP) designation for MET-X by the U.S. Food and Drug Administration (FDA).

Key Points: 
  • STOCKHOLM, Jan. 11, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that its partner Infex Therapeutics, a leading anti-infectives specialist, has been granted Qualified Infectious Disease Product (QIDP) designation for MET-X by the U.S. Food and Drug Administration (FDA).
  • MET-X is the Company's broad spectrum Metallo-beta-lactamase inhibitor (MBLI) based on the MBLI program outlicensed by Medivir in 2017 to the AMR Centre, which changed its name to Infex Therapeutics in 2020.
  • QIDP designation is a U.S. incentive scheme designed to encourage the development of innovative new drugs to treat serious or life-threatening infections.
  • The designation gives MET-X an accelerated FDA regulatory pathway, including priority review, fast-track designation and an additional five years of market exclusivity upon regulatory approval.

DGAP-News: Aurubis AG: Aurubis Supervisory Board extends CEO Roland Harings' mandate by five years

Retrieved on: 
Friday, September 24, 2021
Sustainability, Metallo, Aurubis, News, Board of directors, Supervisory board, DGAP, Selenium, Nickel, Metal, RTÉ Executive Board, CEO, Group, Natural Resources, Growth, Zinc, Lead, Copper, COO, Recycling, CO2, Tin, Security (finance), Cryptocurrency, Pension fund, Management

- CEO's contract now runs until June 30, 2027

Key Points: 
  • - CEO's contract now runs until June 30, 2027
    - Supervisory Board Chairman Prof. Dr. Fritz Vahrenholt: "The company's management is in good hands with Mr. Harings"
    Hamburg, September 24, 2021 - In its meeting yesterday, the Aurubis AG Supervisory Board extended CEO Roland Harings' mandate by five years; as a result, Harings is now appointed until June 30, 2027.
  • "In light of Aurubis AG's successful development in the past two years, I'm pleased that the Supervisory Board has now extended the Executive Board contract by an additional five years," remarks Supervisory Board Chairman Prof. Dr. Fritz Vahrenholt.
  • Beginning October 1, 2021, the Aurubis AG Executive Board will consist of three members: CEO Roland Harings, CFO Rainer Verhoeven (52), and COO Dr. Heiko Arnold (55).
  • The Supervisory Board and Executive Board expressly thank Thomas Bnger for his many years of dedicated work at Aurubis and wish him all the best for his professional and personal life.